Aminacrine

Aminacrine

SCHEMBL29566014

Nc1c2ccccc2nc2ccccc12.O=CO

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 6/20 0.75
KDM4E B2RXH2 5/20 0.75
ALDH1A1 P00352 5/20 0.75
ACHE P22303 3/20 0.75
GLA P06280 2/20 0.75
HPGD P15428 2/20 0.75
CASP1 P29466 2/20 0.75
CASP7 P55210 2/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
MAOA P21397 2/20 0.75
CHRM2 P08172 2/20 0.75
ADRA2A P08913 2/20 0.75
ADORA3 P0DMS8 2/20 0.75
CHRM1 P11229 2/20 0.75
SLC6A2 P23975 2/20 0.75
OPRM1 P35372 2/20 0.75
KCNH2 Q12809 2/20 0.75
NQO2 P16083 1/20 0.75
DRD1 P21728 1/20 0.75
ADRA1A P35348 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aminacrine SCHEMBL29354393 0.87 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1ACHEGLA
Aminacrine SCHEMBL14999 0.87 HSD17B10 (1.00) HSD17B10KDM4EALDH1A1ACHEGLA
Aminacrine SCHEMBL11419528 0.85 ALDH1A1 (0.86) HSD17B10KDM4EALDH1A1ACHEGLA
Aminacrine SCHEMBL14482032 0.84 HSD17B10 (0.95) HSD17B10KDM4EALDH1A1ACHEGLA
Aminacrine SCHEMBL4907467 0.84 HSD17B10 (0.95) HSD17B10KDM4EALDH1A1ACHEGLA
Aminacrine SCHEMBL635597 0.84 RAB9A (1.00) HSD17B10KDM4EALDH1A1ACHEGLA
Aminacrine SCHEMBL31237441 0.84 RAB9A (1.00) HSD17B10KDM4EALDH1A1ACHEGLA
Aminacrine SCHEMBL18989123 0.84 HSD17B10 (0.95) HSD17B10KDM4EALDH1A1ACHEGLA
Aminacrine SCHEMBL30355377 0.84 HSD17B10 (0.95) HSD17B10KDM4EALDH1A1ACHEGLA
Aminacrine SCHEMBL635598 0.84 RAB9A (1.00) HSD17B10KDM4EALDH1A1ACHEGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 HSD17B10 1573/4885KDM4E 42/4885ALDH1A1 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.